CNXU Stock Forecast: Conexeu Sciences, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Conexeu Sciences, Inc. hold a median 12-month price target of $20 — +157.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
CNXU stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Conexeu Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (66): Smaller than most of the companies we track.
Momentum (0): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Conexeu Sciences, Inc. — and when they’d sell — is the membership.
CNXU stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CNXU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +157.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 June 2026 | HC Wainwright & Co. | Initiates | Buy | $20 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CNXU analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Conexeu Sciences, Inc. (CNXU) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −45.4×
- Price / sales
- —
- Price / book
- 24.2×
- EV / EBITDA
- −29.9×
Cheaper than 98% of US stocks
Cheaper than 4% of US stocks
Cheaper than 91% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −53.4%
- Return on assets
- −51.0%
- Dividend yield
- —
Higher than 20% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CNXU vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNXU appears on the weeks it earns a place.
Frequently asked questions about CNXU stock
What is the CNXU stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Conexeu Sciences, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CNXU stock a buy right now?
Of the 1 analysts covering Conexeu Sciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Conexeu Sciences, Inc. 2 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CNXU?
As at 1 Aug 2026, Conexeu Sciences, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (66 of 100).
Will CNXU stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +157.7% from the last close, and Ticker Nerd's factor model ranks Conexeu Sciences, Inc. 2 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CNXU stock forecast for 2030?
No analyst covering Conexeu Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNXU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.
What does Conexeu Sciences, Inc. do?
Conexeu Sciences Inc. is a biotechnology company focused on developing and commercializing therapies in the life sciences and healthcare sector.
About Conexeu Sciences, Inc.
Conexeu Sciences Inc. is a biotechnology company focused on developing and commercializing therapies in the life sciences and healthcare sector. The company concentrates on innovative treatments that aim to address unmet medical needs, leveraging scientific research, clinical development, and regulatory expertise. Conexeu Sciences Inc. typically works across key therapeutic areas where biologics, small molecules, or advanced modalities such as gene or cell-based approaches can play a meaningful role. Its activities span preclinical research, clinical trials, and collaboration with healthcare providers, research institutions, and industry partners to advance candidate therapies toward approval and medical adoption. Founded in the United States, Conexeu Sciences Inc. participates in a highly specialized segment of the healthcare market, where scientific rigor, intellectual property, and regulatory compliance are central to its operations. The company’s role in the financial markets reflects investor interest in the biotechnology industry, which is characterized by a focus on innovation, scientific data, and progress in clinical development programs.
CEO Mr. Miles D. Harrison · United States · https://www.conexeu.com